Jazuli Isyaku Bala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jazuli Isyaku Bala has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Obiageri Ihuarulam Okeoma
Department of Medical Laboratory Science, Faculty of Basic Medical And Applied Sciences, Trinity University, Yaba, Lagos, Nigeria
2 shared publications - Adepeju Kafayat Olowookere
Department of Nanoscience, University of North Carolina at Greensboro, Greensboro, NC, USA
1 shared publication - Adeyinka Moyinoluwa Adejumobi
Department of Data, Artificial Intelligence and Modelling, University of Hull, Hull, UK
1 shared publication - Chidinma Lorretta Gab-Obinna
Biomedical Laboratory Science Department, Kingston University London, London, United Kingdom
1 shared publication - Chidinma Lorretta Gab-Obinna
Biomedical Science Department, Kingston University London, England, UK
1 shared publication - Enobong Edoabasi Obong
Department of Neurology, Washington University, Saint Louis, MO, USA
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 2 (1) , aubm012
Gene Editing Therapies for Sickle Cell Disease and β-Thalassemia: A Systematic Review of Clinical Outcomes and Safety
Background: Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) remain major global health burdens. Ex vivo gene-editing therapies aim to achieve durable fetal hemoglobin (HbF) induction or direct mutation correction. Methods: We systematically reviewed clinical studies of CRISPR-Cas9 or base-editing therapies for SCD and TDT (MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, conference proceedings; 2010–03 December 2025). Eleven studies (>170 treated patients) reporting post-infusion outcomes were included. Results: All therapies produced robust, pancellular HbF (30–65%) and total hemoglobin in/near the normal range. In TDT (n > 100 evaluable), transfusion independence (≥12 months, Hb ≥9 g/dL) was achieved in 89–100% across platforms, sustained up to >4 years. In SCD (n > 60 evaluable), adjudicated vaso-occlusive crises were eliminated for ≥12 months in ≥97% of patients treated with exagamglogene autotemcel and 100% in smaller cohorts (EDIT-301, BEAM-101). No graft failures occurred. Serious adverse events and one death were attributable to busulfan conditioning, not editing. No therapy-related malignancies or confirmed harmful off-target edits have been reported, although follow-up remains limited (median ~18 months, longest >4 years). Conclusion: Current evidence from phase 1–3 trials demonstrates that ex vivo gene editing can achieve functional cure for many patients with TDT and severe SCD. Conditioning-related toxicity, limited long-term safety data, and delivery complexity remain critical barriers to broader implementation.
- 13 January 2026
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 2 (1) , aubm012
Open AccessGene Editing Therapies for Sickle Cell Disease and β-Thalassemia: A Systematic Review of Clinical Outcomes and Safety
Background: Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) remain major global health burdens. Ex vivo gene-editing therapies aim to achieve durable fetal hemoglobin (HbF) induction or direct mutation correction. Methods: We systematically reviewed clinical studies of CRISPR-Cas9 or base-editing therapies for SCD and TDT (MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, conference proceedings; 2010–03 December 2025). Eleven studies (>170 treated patients) reporting post-infusion outcomes were included. Results: All therapies produced robust, pancellular HbF (30–65%) and total hemoglobin in/near the normal range. In TDT (n > 100 evaluable), transfusion independence (≥12 months, Hb ≥9 g/dL) was achieved in 89–100% across platforms, sustained up to >4 years. In SCD (n > 60 evaluable), adjudicated vaso-occlusive crises were eliminated for ≥12 months in ≥97% of patients treated with exagamglogene autotemcel and 100% in smaller cohorts (EDIT-301, BEAM-101). No graft failures occurred. Serious adverse events and one death were attributable to busulfan conditioning, not editing. No therapy-related malignancies or confirmed harmful off-target edits have been reported, although follow-up remains limited (median ~18 months, longest >4 years). Conclusion: Current evidence from phase 1–3 trials demonstrates that ex vivo gene editing can achieve functional cure for many patients with TDT and severe SCD. Conditioning-related toxicity, limited long-term safety data, and delivery complexity remain critical barriers to broader implementation.
- 1 December 2025
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 1 (6) , ehdi023
Artificial Intelligence in Transfusion Medicine: Current Applications, Opportunities, and Challenges
Artificial intelligence (AI) is increasingly shaping modern healthcare by enabling data-driven decision-making, improving diagnostic accuracy, and optimizing resource use. In transfusion medicine, AI offers substantial opportunities to enhance donor management, automate blood typing and compatibility testing, strengthen inventory forecasting, and support early detection of transfusion-related complications. This review summarizes current applications of AI technologies—including machine learning, deep learning, natural language processing, computer vision, and predictive analytics—and evaluates their impact across laboratory, clinical, and operational domains. Emerging innovations such as precision transfusion, patient digital twins, multi-omics integration, and federated learning highlight AI’s potential to advance personalized and interconnected transfusion practices. However, successful implementation requires addressing challenges related to data heterogeneity, algorithmic bias, privacy and ethical considerations, and evolving regulatory requirements. Establishing rigorous validation standards and promoting interdisciplinary collaboration will be essential to ensure that AI improves the safety, efficiency, and sustainability of transfusion medicine.
- 1 December 2025
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 1 (6) , ehdi023
Artificial Intelligence in Transfusion Medicine: Current Applications, Opportunities, and Challenges
Artificial intelligence (AI) is increasingly shaping modern healthcare by enabling data-driven decision-making, improving diagnostic accuracy, and optimizing resource use. In transfusion medicine, AI offers substantial opportunities to enhance donor management, automate blood typing and compatibility testing, strengthen inventory forecasting, and support early detection of transfusion-related complications. This review summarizes current applications of AI technologies—including machine learning, deep learning, natural language processing, computer vision, and predictive analytics—and evaluates their impact across laboratory, clinical, and operational domains. Emerging innovations such as precision transfusion, patient digital twins, multi-omics integration, and federated learning highlight AI’s potential to advance personalized and interconnected transfusion practices. However, successful implementation requires addressing challenges related to data heterogeneity, algorithmic bias, privacy and ethical considerations, and evolving regulatory requirements. Establishing rigorous validation standards and promoting interdisciplinary collaboration will be essential to ensure that AI improves the safety, efficiency, and sustainability of transfusion medicine.